De Perrot, Dr Marc

Arch Biopartners Advances LSALT Peptide Phase II Trial for Cardiac Surgery-Associated Acute Kidney Injury

- St. Michael's Hospital has commenced patient dosing in Arch Biopartners' Phase II trial evaluating LSALT peptide for preventing cardiac surgery-associated acute kidney injury (CS-AKI). - The international multicenter trial targets 240 patients and represents a potential first-in-class therapeutic approach for CS-AKI, which affects up to 30% of cardiac surgery patients. - LSALT peptide works by binding to the DPEP1 enzyme to inhibit organ inflammation, with previous Phase II results showing statistically significant reductions in inflammatory biomarkers. - The company is expanding trial sites to include U.S. centers while also advancing a separate Phase II trial of cilastatin for drug-induced acute kidney injury.